PREMENSTRUAL DYSPHORIC DISORDER (PMDD): CURRENT PHARMACOTHERAPY AND EMERGING TREATMENT APPROACHES
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.6100Keywords:
Premenstrual Dysphoric Disorder; Premenstrual Syndrome; Selective Serotonin Reuptake Inhibitors; Hormonal Therapy; Women's Mental HealthAbstract
Premenstrual dysphoric disorder (PMDD) is a cyclic mood disorder affecting a subset of women in the late luteal phase, marked by severe affective and physical symptoms that resolve with menses. It is distinguished from milder premenstrual syndrome (PMS) by symptom severity and functional impairment. PMDD causes substantial distress: women with PMDD have functional impairments comparable to other depressive disorders and increased work absences, and PMDD is associated with higher rates of suicidal ideation and attempts. First-line pharmacotherapy consists of selective serotonin reuptake inhibitors (SSRIs) and hormone-based treatments. SSRIs (e.g. sertraline, fluoxetine, paroxetine, escitalopram) are effective when dosed continuously or in the luteal phase, often producing rapid symptom relief at low doses. Hormonal therapies (e.g. combined oral contraceptives with drospirenone/ethinyl estradiol, GnRH agonists with add-back) can mitigate symptoms by suppressing cyclic ovarian hormone fluctuations. Emerging treatments target PMDD’s neuroendocrine underpinnings: for example, sepranolone (an allopregnanolone antagonist) has shown promising early results. Novel approaches under investigation include neurosteroid modulators, anti-inflammatory strategies, and personalized interventions (genetic or biomarker-driven therapy). This review summarizes current evidence-based pharmacotherapies for PMDD and discusses emerging treatment avenues based on advances in PMDD neurobiology and psychoneuroendocrinology.
References
Appleton, S. M. (2018). Premenstrual syndrome: Evidence-based evaluation and treatment. Clinical Obstetrics and Gynecology, 61(1), 52–61. https://doi.org/10.1097/GRF.0000000000000339
Bäckström, T., Ekberg, K., Hirschberg, A. L., Bixo, M., Epperson, C. N., Briggs, P., Panay, N., & O’Brien, S. (2021). A randomized, double-blind study on efficacy and safety of sepranolone in premenstrual dysphoric disorder. Psychoneuroendocrinology, 133, 105426. https://doi.org/10.1016/j.psyneuen.2021.105426
Behboudi-Gandevani, S., Hariri, F.-Z., & Moghaddam-Banaem, L. (2018). The effect of omega 3 fatty acid supplementation on premenstrual syndrome and health-related quality of life: A randomized clinical trial. Journal of Psychosomatic Obstetrics and Gynaecology, 39(4), 266–272. https://doi.org/10.1080/0167482X.2017.1348496
Berger, C. P., & Presser, B. (1994). Alprazolam in the treatment of two subsamples of patients with late luteal phase dysphoric disorder: A double-blind, placebo-controlled crossover study. Obstetrics and Gynecology, 84(3), 379–385.
Bertone-Johnson, E. R., Ronnenberg, A. G., Houghton, S. C., Nobles, C., Zagarins, S. E., Takashima-Uebelhoer, B. B., Faraj, J. L., & Whitcomb, B. W. (2014). Association of inflammation markers with menstrual symptom severity and premenstrual syndrome in young women. Human Reproduction, 29(9), 1987–1994. https://doi.org/10.1093/humrep/deu170
Bixo, M., Ekberg, K., Poromaa, I. S., Hirschberg, A. L., Jonasson, A. F., Andréen, L., Timby, E., Wulff, M., Ehrenborg, A., & Bäckström, T. (2017). Treatment of premenstrual dysphoric disorder with the GABA-A receptor modulating steroid antagonist sepranolone (UC1010)—A randomized controlled trial. Psychoneuroendocrinology, 80, 46–55. https://doi.org/10.1016/j.psyneuen.2017.02.031
Busse, J. W., Montori, V. M., Krasnik, C., Patelis-Siotis, I., & Guyatt, G. H. (2009). Psychological intervention for premenstrual syndrome: A meta-analysis of randomized controlled trials. Psychotherapy and Psychosomatics, 78(1), 6–15. https://doi.org/10.1159/000162296
Carlini, S. V., & Deligiannidis, K. M. (2020). Evidence-based treatment of premenstrual dysphoric disorder: A concise review. The Journal of Clinical Psychiatry, 81(2), 19ac13071. https://doi.org/10.4088/JCP.19ac13071
Cary, E., & Simpson, P. (2024). Premenstrual disorders and PMDD—A review. Best Practice & Research Clinical Endocrinology & Metabolism, 38(1), 101858. https://doi.org/10.1016/j.beem.2023.101858
Cho, S.-E., & Na, K.-S. (2019). Questioning the beneficial effects of internet-based cognitive behavioral therapy on premenstrual dysphoric disorder. Psychotherapy and Psychosomatics, 88(4), 236. https://doi.org/10.1159/000499681
Cohen, L. S., Soares, C. N., Lyster, A., Cassano, P., Brandes, M., & Leblanc, G. A. (2004). Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder. Journal of Clinical Psychopharmacology, 24(5), 540–543. https://doi.org/10.1097/01.jcp.0000138767.53976.10
Dehnavi, S. I., Mortazavi, S. S., Ramezani, M. A., Gharraee, B., & Ashouri, A. (2024). Emotion-focused therapy for women with premenstrual dysphoric disorder: A randomized clinical controlled trial. BMC Psychiatry, 24(1), 501. https://doi.org/10.1186/s12888-024-05681-8
Diagnostic and statistical manual of mental disorders | Psychiatry Online. (n.d.). DSM Library. Retrieved June 3, 2026, from https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890425787
Dimmock, P. W., Wyatt, K. M., Jones, P. W., & O’Brien, P. M. (2000). Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: A systematic review. The Lancet, 356(9236), 1131–1136. https://doi.org/10.1016/S0140-6736(00)02754-9
Dubey, N., Hoffman, J. F., Schuebel, K., Yuan, Q., Martinez, P. E., Nieman, L. K., Rubinow, D. R., Schmidt, P. J., & Goldman, D. (2017). The ESC/E(Z) complex, an effector of response to ovarian steroids, manifests an intrinsic difference in cells from women with premenstrual dysphoric disorder. Molecular Psychiatry, 22(8), 1172–1184. https://doi.org/10.1038/mp.2016.229
Eisenlohr-Moul, T. A., Girdler, S. S., Johnson, J. L., Schmidt, P. J., & Rubinow, D. R. (2017). Treatment of premenstrual dysphoria with continuous vs. intermittent dosing of oral contraceptives: Results of a three-arm randomized controlled trial. Depression and Anxiety, 34(10), 908–917. https://doi.org/10.1002/da.22673
Endicott, J., Nee, J., & Harrison, W. (2006). Daily Record of Severity of Problems (DRSP): Reliability and validity. Archives of Women’s Mental Health, 9(1), 41–49. https://doi.org/10.1007/s00737-005-0103-y
Freeman, E. W., Kroll, R., Rapkin, A., Pearlstein, T., Brown, C., Parsey, K., Zhang, P., Patel, H., Foegh, M., & PMS/PMDD Research Group. (2001). Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. Journal of Women’s Health & Gender-Based Medicine, 10(6), 561–569. https://doi.org/10.1089/15246090152543148
Freeman, E. W., Rickels, K., Sondheimer, S. J., Polansky, M., & Xiao, S. (2004). Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder. The American Journal of Psychiatry, 161(2), 343–351. https://doi.org/10.1176/appi.ajp.161.2.343
Freeman, E. W., Rickels, K., Yonkers, K. A., Kunz, N. R., McPherson, M., & Upton, G. V. (2001). Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstetrics and Gynecology, 98(5 Pt 1), 737–744. https://doi.org/10.1016/S0029-7844(01)01530-7
Freeman, E. W., Sondheimer, S. J., & Rickels, K. (1997). Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: A controlled study. Psychopharmacology Bulletin, 33(2), 303–309.
Griffin, L. D., & Mellon, S. H. (1999). Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proceedings of the National Academy of Sciences of the United States of America, 96(23), 13512–13517. https://doi.org/10.1073/pnas.96.23.13512
Halbreich, U., Borenstein, J., Pearlstein, T., & Kahn, L. S. (2003). The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology, 28(Suppl. 3), 1–23. https://doi.org/10.1016/S0306-4530(03)00098-2
Halbreich, U., Freeman, E. W., Rapkin, A. J., Cohen, L. S., Grubb, G. S., Bergeron, R., Smith, L., Mirkin, S., & Constantine, G. D. (2012). Continuous oral levonorgestrel/ethinyl estradiol for treating premenstrual dysphoric disorder. Contraception, 85(1), 19–27. https://doi.org/10.1016/j.contraception.2011.05.008
Hantsoo, L., & Epperson, C. N. (2015). Premenstrual dysphoric disorder: Epidemiology and treatment. Current Psychiatry Reports, 17(11), 87. https://doi.org/10.1007/s11920-015-0628-3
Hantsoo, L., & Epperson, C. N. (2020). Allopregnanolone in premenstrual dysphoric disorder (PMDD): Evidence for dysregulated sensitivity to GABA-A receptor modulating neuroactive steroids across the menstrual cycle. Neurobiology of Stress, 12, 100213. https://doi.org/10.1016/j.ynstr.2020.100213
Hoppe, J. M., Weise, C., Kleinstaeuber, M., Skalkidou, A., Vegelius, J., Comasco, E., Gröndal, M., Kaltsouni, E., Sundström, F., Sampaio, F., Andersson, G., & Buhrman, M. (2025). Emotion regulation-based internet-delivered cognitive behavioural therapy for premenstrual dysphoric disorder: Study protocol for a randomised controlled trial in Sweden. BMJ Open, 15(1), e091649. https://doi.org/10.1136/bmjopen-2024-091649
Hsiao, M.-C., & Liu, C.-Y. (2003). Effective open-label treatment of premenstrual dysphoric disorder with venlafaxine. Psychiatry and Clinical Neurosciences, 57(3), 317–321. https://doi.org/10.1046/j.1440-1819.2003.01123.x
Hunter, M. S., Ussher, J. M., Browne, S. J., Cariss, M., Jelley, R., & Katz, M. (2002). A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder. Journal of Psychosomatic Obstetrics and Gynaecology, 23(3), 193–199. https://doi.org/10.3109/01674820209074672
Jackson, C., Pearson, B., Girdler, S., Johnson, J., Hamer, R. M., Killenberg, S., & Meltzer-Brody, S. (2015). Double-blind, placebo-controlled pilot study of adjunctive quetiapine SR in the treatment of PMS/PMDD. Human Psychopharmacology, 30(6), 425–434. https://doi.org/10.1002/hup.2494
Jespersen, C., Lauritsen, M. P., Frokjaer, V. G., & Schroll, J. B. (2024). Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder. Cochrane Database of Systematic Reviews, 2024(8), CD001396. https://doi.org/10.1002/14651858.CD001396.pub4
Kleinstäuber, M., Witthöft, M., & Hiller, W. (2012). Cognitive-behavioral and pharmacological interventions for premenstrual syndrome or premenstrual dysphoric disorder: A meta-analysis. Journal of Clinical Psychology in Medical Settings, 19(3), 308–319. https://doi.org/10.1007/s10880-012-9299-y
Lanza di Scalea, T., & Pearlstein, T. (2019). Premenstrual dysphoric disorder. The Medical Clinics of North America, 103(4), 613–628. https://doi.org/10.1016/j.mcna.2019.02.007
Loukzadeh, Z., Eslamy, N., Dehghan, M., & Houshang Mehrparvar, A. (2024). The impact of premenstrual disorders on work disruptions among working women: A cross-sectional study. International Journal of Reproductive Biomedicine, 22(2), 149–156. https://doi.org/10.18502/ijrm.v22i2.15712
Ma, S., & Song, S. J. (2023). Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database of Systematic Reviews, 2023(6), CD006586. https://doi.org/10.1002/14651858.CD006586.pub5
Maharaj, S., & Trevino, K. (2015). A comprehensive review of treatment options for premenstrual syndrome and premenstrual dysphoric disorder. Journal of Psychiatric Practice, 21(5), 334–350. https://doi.org/10.1097/PRA.0000000000000099
Management of premenstrual disorders. (2023). https://www.acog.org/clinical/clinical-guidance/clinical-practice-guideline/articles/2023/12/management-of-premenstrual-disorders
Marais-Thomas, H., Chapelle, F., de Vaux-Boitouzet, V., & Bouvet, C. (2024). [Premenstrual dysphoric disorder (PMDD): Drug and psychotherapeutique management, a literature review]. L’Encephale, 50(2), 211–232. https://doi.org/10.1016/j.encep.2023.08.007
Marjoribanks, J., Proctor, M., Farquhar, C., & Derks, R. S. (2010). Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database of Systematic Reviews, 2010(1), CD001751. https://doi.org/10.1002/14651858.CD001751.pub2
Mazza, M., Harnic, D., Catalano, V., Janiri, L., & Bria, P. (2008). Duloxetine for premenstrual dysphoric disorder: A pilot study. Expert Opinion on Pharmacotherapy, 9(4), 517–521. https://doi.org/10.1517/14656566.9.4.517
Mohammadi, M. M., Dehghan Nayeri, N., Mashhadi, M., & Varaei, S. (2022). Effect of omega-3 fatty acids on premenstrual syndrome: A systematic review and meta-analysis. The Journal of Obstetrics and Gynaecology Research, 48(6), 1293–1305. https://doi.org/10.1111/jog.15217
Naheed, B., Kuiper, J. H., O’Mahony, F., & O’Brien, P. M. (2025). Gonadotropin-releasing hormone (GnRH) analogues for premenstrual syndrome (PMS). Cochrane Database of Systematic Reviews, 2025(6), CD011330. https://doi.org/10.1002/14651858.CD011330.pub2
Nazari, H., Yari, F., Jariani, M., Marzban, A., & Birgandy, M. (2013). Premenstrual syndrome: A single-blind study of treatment with buspirone versus fluoxetine. Archives of Gynecology and Obstetrics, 287(3), 469–472. https://doi.org/10.1007/s00404-012-2594-x
Nguyen, A. T. (2024). U.S. medical eligibility criteria for contraceptive use, 2024. MMWR Recommendations and Reports, 73. https://doi.org/10.15585/mmwr.rr7304a1
Nguyen, T. V., Reuter, J. M., Gaikwad, N. W., Rotroff, D. M., Kucera, H. R., Motsinger-Reif, A., Smith, C. P., Nieman, L. K., Rubinow, D. R., Kaddurah-Daouk, R., & Schmidt, P. J. (2017). The steroid metabolome in women with premenstrual dysphoric disorder during GnRH agonist-induced ovarian suppression: Effects of estradiol and progesterone addback. Translational Psychiatry, 7(8), e1193. https://doi.org/10.1038/tp.2017.146
Pearlstein, T., & Steiner, M. (2008). Premenstrual dysphoric disorder: Burden of illness and treatment update. Journal of Psychiatry & Neuroscience, 33(4), 291–301.
Pinna, G., Costa, E., & Guidotti, A. (2006). Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake. Psychopharmacology, 186(3), 362–372. https://doi.org/10.1007/s00213-005-0213-2
Prasad, D., Wollenhaupt-Aguiar, B., Kidd, K. N., de Azevedo Cardoso, T., & Frey, B. N. (2021). Suicidal risk in women with premenstrual syndrome and premenstrual dysphoric disorder: A systematic review and meta-analysis. Journal of Women’s Health, 30(12), 1693–1707. https://doi.org/10.1089/jwh.2021.0185
Ramos, M. G., Hara, C., & Rocha, F. L. (2009). Duloxetine treatment for women with premenstrual dysphoric disorder: A single-blind trial. The International Journal of Neuropsychopharmacology, 12(8), 1081–1088. https://doi.org/10.1017/S1461145709000066
Reilly, T. J., Patel, S., Unachukwu, I. C., Knox, C.-L., Wilson, C. A., Craig, M. C., Schmalenberger, K. M., Eisenlohr-Moul, T. A., & Cullen, A. E. (2024). The prevalence of premenstrual dysphoric disorder: Systematic review and meta-analysis. Journal of Affective Disorders, 349, 534–540. https://doi.org/10.1016/j.jad.2024.01.066
Reilly, T. J., Wallman, P., Clark, I., Knox, C.-L., Craig, M. C., & Taylor, D. (2023). Intermittent selective serotonin reuptake inhibitors for premenstrual syndromes: A systematic review and meta-analysis of randomised trials. Journal of Psychopharmacology, 37(3), 261–267. https://doi.org/10.1177/02698811221099645
Sani, G., Kotzalidis, G. D., Panaccione, I., Simonetti, A., De Chiara, L., Del Casale, A., Ambrosi, E., Napoletano, F., Janiri, D., Danese, E., Girardi, N., Rapinesi, C., Serata, D., Manfredi, G., Koukopoulos, A. E., Angeletti, G., Nicoletti, F., & Girardi, P. (2014). Low-dose acetazolamide in the treatment of premenstrual dysphoric disorder: A case series. Psychiatry Investigation, 11(1), 95–101. https://doi.org/10.4306/pi.2014.11.1.95
Schmidt, P. J., Martinez, P. E., Nieman, L. K., Koziol, D. E., Thompson, K. D., Schenkel, L., Wakim, P. G., & Rubinow, D. R. (2017). Premenstrual dysphoric disorder symptoms following ovarian suppression: Triggered by change in ovarian steroid levels but not continuous stable levels. The American Journal of Psychiatry, 174(10), 980–989. https://doi.org/10.1176/appi.ajp.2017.16101113
Tiranini, L., & Nappi, R. E. (2022). Recent advances in understanding/management of premenstrual dysphoric disorder/premenstrual syndrome. Faculty Reviews, 11, 11. https://doi.org/10.12703/r/11-11
Weise, C., Kaiser, G., Janda, C., Kues, J. N., Andersson, G., Strahler, J., & Kleinstäuber, M. (2019). Internet-based cognitive-behavioural intervention for women with premenstrual dysphoric disorder: A randomized controlled trial. Psychotherapy and Psychosomatics, 88(1), 16–29. https://doi.org/10.1159/000496237
Wittchen, H.-U., Becker, E., Lieb, R., & Krause, P. (2002). Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychological Medicine, 32(1), 119–132. https://doi.org/10.1017/S0033291701004925
Yonkers, K. A., Brown, C., Pearlstein, T. B., Foegh, M., Sampson-Landers, C., & Rapkin, A. (2005). Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstetrics and Gynecology, 106(3), 492–501. https://doi.org/10.1097/01.AOG.0000175834.77215.2e
Yonkers, K. A., Kornstein, S. G., Gueorguieva, R., Merry, B., Van Steenburgh, K., & Altemus, M. (2015). Symptom-onset dosing of sertraline for the treatment of premenstrual dysphoric disorder: A randomized clinical trial. JAMA Psychiatry, 72(10), 1037–1044. https://doi.org/10.1001/jamapsychiatry.2015.1472
Yonkers, K. A., O’Brien, P. M. S., & Eriksson, E. (2008). Premenstrual syndrome. The Lancet, 371(9619), 1200–1210. https://doi.org/10.1016/S0140-6736(08)60527-9
Yonkers, K. A., Pearlstein, T., Fayyad, R., & Gillespie, J. A. (2005). Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase. Journal of Affective Disorders, 85(3), 317–321. https://doi.org/10.1016/j.jad.2004.10.006
ZOLOFT (sertraline hydrochloride) label. (n.d.). Retrieved June 4, 2026, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019839s74s86s87_20990s35s44s45lbl.pdf
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Julia Oziębło, Magdalena Kijowska, Karolina Klusek, Michał Batory, Jakub Jakubowski, Karol Kraska, Nadzieja Krasucka, Aleksandra Zynkowska, Aleksandra Magdalena Skrzyniarz, Maria Kiełbus
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
